The PARP inhibitor Olaparib is recommended for early TNBC patients showing no pCR and harboring gBRCA1/2 mutations as well as for high-risk gBRCA1/2 mutant HR-positive/HER2-negative early BC patients as proven in the OLYMPIA trial [98,231] (Table 7). The gene discussed is ERBB2; the disease is breast cancer.